Convalescent Plasma Therapy in COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS)
DOI:
https://doi.org/10.36497/jri.v43i2.413Keywords:
ARDS, COVID-19, Convalence Plasma TherapyAbstract
COVID-19 is caused by SARS-CoV-1, an RNA virus of the betacoronavirus genus, making it the seventh coronavirus infecting humans. Because particular therapies are still in the research stage, no confirmed treatment for this illness has been agreed upon by the World Health Organization (WHO) or other clinical institutes. The reason is that there are many different potential remedies. Antiviral treatments like favipiravir, oseltamivir, and remdesivir have been investigated and tested. On the other hand, the outcomes of the replies of patients who were given these medications are still quite inconsistent. Furthermore, the COVID-19 mortality rate has remained at a level of less than 5.21 percent of cases that have been documented. Patients suffering from COVID-19 may be treated with convalescent plasma, a therapeutic option that utilizes a mix of neutralizing antibodies and other immunological components. Activation of body-dependent cellular cytotoxicity (ADCC) and phagocytic activity against COVID-19 will occur due to this immunological component. This medication also has the potential to reduce the systemic inflammatory response brought on by COVID-19. Clinical improvement was different after 28 days when convalescent plasma was used as a treatment for patients with severe COVID-19 symptoms and emergency conditions compared to patients treated with conventional therapy alone. However, it is not very significant.
Downloads
References
Putera DD, Hardianti MS. Efficacy and safety of convalescent plasma therapy in patients with COVID-19: A rapid review of case series. Journal of the Medical Sciences (Berkala Ilmu Kedokteran). 2020;52(3):134–47.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. Brief report: A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20(4):398–400.
Beeching NJ, Fletcher TE, Fowler R. Coronavirus disease 2019 (COVID-19). BMJ Best Practice. 2020.
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P. Convalescent plasma in the management of moderate covid-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371.
Guan W jie, Ni Z yi, Hu Y, Liang W hua, Ou C quan, He J xing, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708–20.
Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757–65.
Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. bioRxiv. 2020;584(7821):437–42.
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–9.
World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020 [Internet]. Geneva; 2020 [cited 2020 Apr 16]. Available from: https://apps.who.int/iris/handle/10665/331446
Dewi KN, Jaya W, Fatoni AZ. Hidrotoraks masif dekstra dengan penyulit ARDS akibat komplikasi pemasangan kateter vena sentral jugular interna. Jurnal Anestesi Perioperatif. 2020;8(2):119–30.
Mccormack V, Sci M, Frca M, Tolhurst-Cleaver S, Mrcp Fficm M. Acute respiratory distress syndrome. BJA Educ. 2017;17(5):161–5.
Kim WY, Hong SB. Sepsis and acute respiratory distress syndrome: Recent update. Tuberc Respir Dis (Seoul). 2016;79(2):53–7.
Bakhtiar A, Maranatha RA. Acute respiratory distress syndrome. Jurnal Respirasi. 2018;4(2):51–60.
Dai W, Gu H, Hao S. Potential benefits, mechanisms, and uncertainties of convalescent plasma therapy for COVID-19. Blood Science. 2020;2(3):71–5.
Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. 2020;383(25):2451–60.
Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science (1979). 2020;368(6490):473–4.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–8.
Kang S, Tanaka T, Narazaki M, Kishimoto T. Targeting interleukin-6 signaling in clinic. Immunity. 2019;50(4):1007–23.
Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy. 2016;8(8):959–70.
Azmi NU, Puteri MU, Lukmanto D. Cytokine storm in COVID-19: An overview, mechanism, treatment strategies, and stem cell therapy perspective. Pharmaceutical Sciences and Research. 2020;7(4):1–11.
Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181–93.
Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607–13.
Park A, Iwasaki A. Type I and Type III interferons - induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27(6):870–8.
Zhao Q, He Y. Challenges of convalescent plasma therapy on COVID-19. Journal of Clinical Virology. 2020;127:104358.
Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA. 2020;324(5):460–70.
Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.
Simonovich VA, Burgos Pratx LD, Scibona P, Beruto M V., Vallone MG, Vázquez C, et al. A randomized trial of convalescent plasma in Covid-19 severe pneumonia. New England Journal of Medicine. 2021;384(7):619–29.
Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020;92(9):1475–83.
Franchini M, Prefumo F, Grisolia G, Bergamini V, Glingani C, Pisello M, et al. Convalescent plasma for pregnant women with COVID-19: A systematic literature review. Viruses. 2021;13(7):1194.
Di Guardo F, Di Grazia FM, Di Gregorio LM, Zambrotta E, Carrara G, Gulino FA, et al. Poor maternal-neonatal outcomes in pregnant patients with confirmed SARS-Cov-2 infection: Analysis of 145 cases. Arch Gynecol Obstet. 2021;303(6):1483–8.
Salem D, Katranji F, Bakdash T. COVID-19 infection in pregnant women: Review of maternal and fetal outcomes. International journal of gynaecology and obstetrics. 2021;152(3):291–8.
Hessami K, Homayoon N, Hashemi A, Vafaei H, Kasraeian M, Asadi N. COVID-19 and maternal, fetal and neonatal mortality: A systematic review. The journal of maternal-fetal & neonatal medicine. 2022;35(15):2936–41.
Di Martino D, Chiaffarino F, Patanè L, Prefumo F, Vergani P, Ornaghi S, et al. Assessing risk factors for severe forms of COVID-19 in a pregnant population: A clinical series from Lombardy, Italy. International journal of gynaecology and obstetrics. 2021;152(2):275–7.
Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610–8.
Downloads
Additional Files
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
